Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma

Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–300.

Article  CAS  PubMed  Google Scholar 

Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–20.

Article  PubMed  Google Scholar 

Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.

Article  CAS  PubMed  Google Scholar 

Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: A controlled cross-sectional study. Hypertension. 2013;62:331–6.

Article  CAS  PubMed  Google Scholar 

Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, et al. Autoimmune mechanisms activating the angiotensin AT1 receptor in ‘primary’ aldosteronism. J Clin Endocrinol Metab. 2014;99:1790–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossitto G, Regolisti G, Rossi E, Negro A, Nicoli D, Casali B, et al. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. Hypertension. 2013;61:526–33.

Article  CAS  PubMed  Google Scholar 

Sabbadin C, Ceccato F, Ragazzi E, Boscaro M, Betterle C, Armanini D. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. J Clin Hypertens. 2018;20:1313–8.

Article  CAS  Google Scholar 

Piazza M, Seccia TM, Caroccia B, Rossitto G, Scarpa R, Persichitti P, et al. AT1AA (Angiotensin II type-1 receptor autoantibodies) cause or consequence of human primary aldosteronism? Hypertension. 2019;74:793–9.

Article  CAS  PubMed  Google Scholar 

Miller AG, Tan G, Binger KJ, Pickering RJ, Thomas MC, Nagaraj RH, et al. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes. 2010;59:3208–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sousa Silva M, Gomes RA, Ferreira AEN, Ponces Freire A, Cordeiro C. The glyoxalase pathway: The first hundred years… and beyond. Biochem J 2013;453:1–15.

Article  CAS  PubMed  Google Scholar 

Hanssen NMJ, Stehouwer CDA, Schalkwijk CG. Methylglyoxal and glyoxalase I in atherosclerosis. Biochem Soc Trans. 2014;42:443–9.

Article  CAS  PubMed  Google Scholar 

Maessen DEM, Stehouwer CDA, Schalkwijk CG. The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. Clin Sci. 2015;128:839–61.

Article  CAS  Google Scholar 

Seccia TM, Caroccia B, Gomez-Sanchez EP, Gomez-Sanchez CE, Rossi GP. The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications. Endocr Rev. 2018;39:1029–56.

PubMed  PubMed Central  Google Scholar 

Scheijen JLJM, Schalkwijk CG. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: Evaluation of blood specimen. Clin Chem Lab Med. 2014;52:85–91.

Article  CAS  PubMed  Google Scholar 

Scheijen JLJM, Hanssen NMJ, Van De Waarenburg MPH, Jonkers DMAE, Stehouwer CDA, Schalkwijk CG. L(+) and D(-) lactate are increased in plasma and urine samples of type 2 diabetes as measured by a simultaneous quantification of L(+) and D(-) lactate by reversed-phase liquid chromatography tandem mass spectrometry. Exp Diabetes Res. 2012;2012:234812.

Article  PubMed  PubMed Central  Google Scholar 

Hanssen NMJ, Engelen L, Ferreira I, Scheijen JLJM, Huijberts MS, van Greevenbroek MMJ, et al. Plasma Levels of Advanced Glycation Endproducts Nϵ -(carboxymethyl)lysine, Nϵ -(carboxyethyl)lysine, and Pentosidine Are not Independently Associated With Cardiovascular Disease in Individuals With or Without Type 2 Diabetes: The H. J Clin Endocrinol Metab. 2013;98:E1369–E1373.

Article  CAS  PubMed  Google Scholar 

Miyata T, Van Ypersele De Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478–87.

Article  CAS  PubMed  Google Scholar 

Monacelli F, Poggi A, Storace D, Durante A, Traverso N, Viviani GL, et al. Effects of valsartan therapy on protein glycoxidation. Metabolism. 2006;55:1619–24.

Article  CAS  PubMed  Google Scholar 

Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl. 2004;66:S105–S107.

Article  Google Scholar 

Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51:3274–82.

Article  CAS  PubMed  Google Scholar 

Chen ZW, Tsai CH, Pan CT, Chou CH, Liao CW, Hung CS, et al. Endothelial dysfunction in primary aldosteronism. Int J Mol Sci. 2019;20:5214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Remde H, Dietz A, Emeny R, Riester A, Peters A, De Las Heras Gala T, et al. The cardiovascularmarkers copeptin and highsensitive C-reactive protein decrease following specific therapy for primary aldosteronism. J Hypertens. 2016;34:2066–73.

Article  CAS  PubMed  Google Scholar 

Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, et al. Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. Eur J Prev Cardiol. 2022;29:e85–e93.

Article  PubMed  Google Scholar 

Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, et al. Primary aldosteronism continuum of renin-independent aldosteronism in normotension. Hypertension. 2017;68:950–7.

Article  Google Scholar 

Šomlóová Z, Petrák O, Rosa J, Štrauch B, Indra T, Zelinka T, et al. Inflammatory markers in primary aldosteronism. Physiol Res. 2016;65:229–37.

Article  PubMed  Google Scholar 

van der Heijden CDCC, Smeets EMM, Aarntzen EHJG, Noz MP, Monajemi H, Kersten S, et al. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism. J Clin Endocrinol Metab. 2020;105:1–14.

Google Scholar 

留言 (0)

沒有登入
gif